| Date Filed | Type | Description |
| 07/19/2013 |
8-K
| Quarterly results |
| 07/17/2013 |
8-K
| Other Events, Financial Statements and Exhibits |
| 04/01/2013 |
8-K
| Quarterly results|
Docs:
|
"Talon Therapeutics, Inc. Reports Fourth Quarter and Year End 2012 Financial Results South San Francisco, California, April 1, 2013 - Talon Therapeutics, Inc., , today reported financial results for the fourth quarter and year ended December 31, 2012. 2012 Corporate Highlights ● FDA accelerated approval of Marqibo® for the treatment of Philadelphia chromosome negative adult acute lymphoblastic leukemia patients in second or greater relapse or whose disease has progressed following two or more prior lines of anti-leukemia therapy. ● Enrollment and dosing of the first patient in the Phase 3 confirmatory study of Marqibo®, named HALLMARQ, in adult patients with newly diagnosed Philadelphia chromosome negative ALL. ● Publication of the Marqibo® RALLY Study in the Journal of Cl..." |
|
| 01/25/2013 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 01/11/2013 |
8-K
| Unregistered Sales of Equity Securities |
| 01/07/2013 |
8-K
| Other Events, Financial Statements and Exhibits |
| 01/04/2013 |
8-K
| Appointed a new director |
| 11/14/2012 |
8-K
| Quarterly results|
Docs:
|
"Three Months Ended September 30, 2012 Financial Results For the three months ended September 30, 2012, Talon reported net income of $40.5 million and deemed dividends attributable to preferred stock of $10.7 million, which when combined, resulted in net income applicable to common stockholders of $29.8 million, or $1.35 and $0.18 basic and diluted earnings per share, respectively. This compares to a net loss of $0.7 million and deemed dividends of $1.0 million, which when combined, resulted in a net loss of $1.7 million, or $0.08 per share, for the three months ended September 30, 2011. The change in fair value of Talon’s preferred stockholders’ rights to purchase additional shares of preferred stock contributed $48.0 million, or $2.19 per share, of total net income applicable to common st..." |
|
| 08/17/2012 |
8-K
| Unregistered Sales of Equity Securities |
| 07/18/2012 |
8-K
| Entry into a Material Definitive Agreement, Other Events |
| 07/05/2012 |
8-K
| Form 8-K - Current report |
| 04/24/2012 |
8-K
| Appointed a new director |
| 04/06/2012 |
8-K
| Form 8-K - Current report |
| 02/24/2012 |
8-K
| Form 8-K - Current report |
| 01/09/2012 |
8-K
| Form 8-K - Current report |
| 12/30/2011 |
8-K
| Form 8-K - Current report |
| 12/19/2011 |
8-K
| Appointed a new director |
| 10/21/2011 |
8-K
| Form 8-K - Current report |
| 09/27/2011 |
8-K
| Other Events, Financial Statements and Exhibits |
| 08/19/2011 |
8-K
| Form 8-K - Current report |
| 07/19/2011 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits |
| 07/01/2011 |
8-K
| Other Events, Financial Statements and Exhibits |
| 01/12/2011 |
8-K
| Form 8-K - Current report |
| 12/28/2010 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 12/02/2010 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits |
| 09/22/2010 |
8-K
| Form 8-K - Current report |
| 09/14/2010 |
8-K
| Form 8-K - Current report |
| 09/03/2010 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 08/05/2010 |
8-K
| Form 8-K - Current report |
| 06/11/2010 |
8-K
| Form 8-K - Current report |
| 03/11/2010 |
8-K
| Form 8-K - Current report |
| 02/22/2010 |
8-K
| Form 8-K - Current report |
| 12/23/2009 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 11/05/2009 |
8-K
| Form 8-K - Current report |
|